Predicate |
Object |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55555 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6018 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-385 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-646 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 |
filingDate |
2004-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2006-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2006528650-A |
titleOfInvention |
Therapeutic vaccine targeting P-glycoprotein 170 to suppress multidrug resistance in cancer treatment |
abstract |
The present invention is derived from the extracellular loop of the P-170 protein, first as a carrier and secondly as an antigenic structure to allow induction of anti-P-170 antibodies under suitable administration conditions An immunogenic composition comprising a conjugate comprising all or part of the amino acid sequence of at least one peptide, wherein each peptide is combined with several fatty acid molecules comprising a C12 to C24 carbon chain The present invention relates to a sex composition. The present invention relates to said composition for defining a means for treating multidrug resistance. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013534523-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2011251964-A |
priorityDate |
2003-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |